Use of Voriconazole to Successfully Treat Disseminated Trichosporon asahii Infection in a Patient with Acute Myeloid Leukaemia

Fournier, Sandra; Pavageau, W; Feuillhade, M; Deplus, S; Am, Zagdanski; Verola, O.; Dombret, Hervé; Jm, Molina

doi:10.1007/s10096-002-0841-y

Cited by 83 publications

(37 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fournier et al. reported a case of disseminated trichosporonosis that was refractory to combination therapy with fluconazole and AmB despite the fact that hematologic recovery was achieved, but the infection was later resolved with voriconazole. Matsue et al.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of Trichosporon fungemia in a patient with refractory acute myeloid leukemia using voriconazole combined with liposomal amphotericin B

Hosokawa

Yamazaki

Mochizuki

et al. 2011

Transplant Infectious Dis

View full text Add to dashboard Cite

Trichosporon fungemia is a rare and fatal fungal infection that occurs in patients with prolonged neutropenia associated with hematologic malignancies. A 21-year-old male developed Trichosporon fungemia during remission induction therapy for acute myeloid leukemia (AML). Although two courses of induction therapy failed to induce a remission of AML, combination therapy with voriconazole and liposomal amphotericin B (L-AmB) followed by monocyte colony-stimulating factor ameliorated the Trichosporon fungemia and enabled the patient to receive reduced-intensity bone marrow transplantation (BMT) from his human leukocyte antigen-A one-locus mismatched mother. The patient achieved a durable remission after BMT without exacerbation of Trichosporon fungemia. The combination therapy with voriconazole and L-AmB may therefore be useful in controlling Trichosporon fungemia associated with prolonged neutropenia after remission induction therapy for AML.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful treatment of Trichosporon fungemia in a patient with refractory acute myeloid leukemia using voriconazole combined with liposomal amphotericin B

Hosokawa

Yamazaki

Mochizuki

et al. 2011

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…Emerging experience suggests that azoles are the primary drug class for the treatment of invasive trichosporonosis [192,232,233,237,238,260,261]. Several of the species are resistant in vitro to amphotericin B with MICs ≥2 mg/L, including T. asahii [256,257,262,263].…”

Section: Susceptibility Testing and Treatmentmentioning

confidence: 99%

“…However, variations in susceptibility in vitro may suggest that not all species and isolates are equally susceptible to this agent [257]. Voriconazole is the preferred agent because it displays good in vitro activity against most Trichosporon species and isolates and has been associated with good in vivo outcome in most cases of clinical and animal studies [232,233,256,261,263,[269][270][271]. In addition to triazole treatment, resolution of myelosuppression and removal of vascular catheters are other confounders related with increased survival [28,192,231,237,238].…”

Section: Susceptibility Testing and Treatmentmentioning

confidence: 99%

ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections

Arendrup

Boekhout

Akova

et al. 2014

Clinical Microbiology and Infection

432

396

View full text Add to dashboard Cite

The mortality associated with invasive fungal infections remains high with that involving rare yeast pathogens other than Candida being no exception. This is in part due to the severe underlying conditions typically predisposing patients to these healthcare-related infections (most often severe neutropenia in patients with haematological malignancies), and in part due to the often challenging intrinsic susceptibility pattern of the pathogens that potentially leads to delayed appropriate antifungal treatment. A panel of experts of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and the European Confederation of Medical Mycology (ECMM) undertook a data review and compiled guidelines for the diagnostic tests and procedures for detection and management of rare invasive yeast infections. The rare yeast pathogens were defined and limited to the following genera/species: Cryptococcus adeliensis, Cryptococcus albidus, Cryptococcus curvatus, Cryptococcus flavescens, Cryptococcus laurentii and Cryptococcus uniguttulatus (often published under the name Filobasidium uniguttulatum), Malassezia furfur, Malassezia globosa, Malassezia pachydermatis and Malassezia restricta, Pseudozyma spp., Rhodotorula glutinis, Rhodotorula minuta and Rhodotorula mucilaginosa, Sporobolomyces spp., Trichosporon asahii, Trichosporon asteroides, Trichosporon dermatis, Trichosporon inkin, Trichosporon jirovecii, Trichosporon loubieri, Trichosporon mucoides and Trichosporon mycotoxinivorans and ascomycetous ones: Geotrichum candidum, Kodamaea ohmeri, Saccharomyces cerevisiae (incl. S. boulardii) and Saprochaete capitatae (Magnusiomyces (Blastoschizomyces) capitatus formerly named Trichosporon capitatum or Geotrichum (Dipodascus) capitatum) and Saprochaete clavata. Recommendations about the microbiological investigation and detection of invasive infection were made and current knowledge on the most appropriate antifungal and supportive treatment was reviewed. In addition, remarks about antifungal susceptibility testing were made.

show abstract

“…Clinical data confirm that azoles improve response rates (CIII) [4, 150, 169] and markedly voriconazole (B III) has been used in patients with hematological malignancies [8, 9, 44, 46, 51, 150] (see Table 5). As high MIC values correspond to low response rates in hematological patients receiving amphotericin B [51] or an echinocandin [17, 53, 105], these agents cannot be recommended as monotherapy (DIII).…”

Section: Treatment Of Trichosporon Infectionsmentioning

confidence: 99%

Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

et al. 2013

View full text Add to dashboard Cite

The Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) here presents its updated recommendations for the treatment of documented fungal infections. Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. In recent years, new antifungal agents have been licensed, and agents already approved have been studied in new indications. The choice of the most appropriate antifungal treatment depends on the fungal species suspected or identified, the patient’s risk factors (e.g., length and depth of neutropenia), and the expected side effects. This guideline reviews the clinical studies that served as a basis for the following recommendations. All recommendations including the levels of evidence are summarized in tables to give the reader rapid access to the information.

show abstract

Use of Voriconazole to Successfully Treat Disseminated Trichosporon asahii Infection in a Patient with Acute Myeloid Leukaemia

Cited by 83 publications

References 36 publications

Successful treatment of Trichosporon fungemia in a patient with refractory acute myeloid leukemia using voriconazole combined with liposomal amphotericin B

Successful treatment of Trichosporon fungemia in a patient with refractory acute myeloid leukemia using voriconazole combined with liposomal amphotericin B

ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections

Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Contact Info

Product

Resources

About